Review



pool 138 peptides derived cmv pp65 protein epitopes  (BEI Resources)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BEI Resources pool 138 peptides derived cmv pp65 protein epitopes
    p53MVA/pembrolizumab activate persistent p53-specific CD8+ T cell responses in the blood the timing of which correlates with lymphocytic infiltration of the resolved dermal metastases. The response of CD8+ (A) and CD4+ (B) T cells from PBMCs after 24-h stimulation culture with p53MVA, MVA, p5396, and pp65138, as determined by flow cytometric analysis. The upregulation of CD137 expression on the surface of CD3+CD8+ T cells reflects increased frequencies of p53-specific T cells in the circulation after vaccination, particularly between weeks 9 and 24. Culture conditions: NIL – medium alone; p53(96) – pool of peptides derived from wild type p53 sequence; <t>pp65(138)</t> – control peptides derived from pp65 <t>CMV;</t> MVA – wild type MVA vaccinia virus; p53MVA – recombinant MVA virus. Bar graphs (C-F) show the frequency of CD8+ T cell subsets quantified from multiplexed immunohistochemistry skin biopsy sections before and 9 weeks into the treatment. Total CD8+ cell count decreased in the skin tissue at week 9 into the treatment (C). However, increased proportions of CD8+CD137+ (D) and CD8+PD-1+ (E) activated T cells as well as CD8+CD103+ tissue resident effector/memory T cells (F) in the skin tissue at week 9, compared with pre-treatment, suggest that these cells contribute to the elimination of cutaneous metastases in situ.
    Pool 138 Peptides Derived Cmv Pp65 Protein Epitopes, supplied by BEI Resources, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pool+138+peptides+derived+cmv+pp65+protein+epitopes/pool+138+peptides+derived+cmv+pp65+protein+epitopes/pmc05706612-238-68-77
    Average 90 stars, based on 1 article reviews
    pool 138 peptides derived cmv pp65 protein epitopes - by Bioz Stars, 2026-10
    90/100 stars

    Images

    1) Product Images from "Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab"

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

    Journal: Oncoimmunology

    doi: 10.1080/2162402X.2017.1363138

    p53MVA/pembrolizumab activate persistent p53-specific CD8+ T cell responses in the blood the timing of which correlates with lymphocytic infiltration of the resolved dermal metastases. The response of CD8+ (A) and CD4+ (B) T cells from PBMCs after 24-h stimulation culture with p53MVA, MVA, p5396, and pp65138, as determined by flow cytometric analysis. The upregulation of CD137 expression on the surface of CD3+CD8+ T cells reflects increased frequencies of p53-specific T cells in the circulation after vaccination, particularly between weeks 9 and 24. Culture conditions: NIL – medium alone; p53(96) – pool of peptides derived from wild type p53 sequence; pp65(138) – control peptides derived from pp65 CMV; MVA – wild type MVA vaccinia virus; p53MVA – recombinant MVA virus. Bar graphs (C-F) show the frequency of CD8+ T cell subsets quantified from multiplexed immunohistochemistry skin biopsy sections before and 9 weeks into the treatment. Total CD8+ cell count decreased in the skin tissue at week 9 into the treatment (C). However, increased proportions of CD8+CD137+ (D) and CD8+PD-1+ (E) activated T cells as well as CD8+CD103+ tissue resident effector/memory T cells (F) in the skin tissue at week 9, compared with pre-treatment, suggest that these cells contribute to the elimination of cutaneous metastases in situ.
    Figure Legend Snippet: p53MVA/pembrolizumab activate persistent p53-specific CD8+ T cell responses in the blood the timing of which correlates with lymphocytic infiltration of the resolved dermal metastases. The response of CD8+ (A) and CD4+ (B) T cells from PBMCs after 24-h stimulation culture with p53MVA, MVA, p5396, and pp65138, as determined by flow cytometric analysis. The upregulation of CD137 expression on the surface of CD3+CD8+ T cells reflects increased frequencies of p53-specific T cells in the circulation after vaccination, particularly between weeks 9 and 24. Culture conditions: NIL – medium alone; p53(96) – pool of peptides derived from wild type p53 sequence; pp65(138) – control peptides derived from pp65 CMV; MVA – wild type MVA vaccinia virus; p53MVA – recombinant MVA virus. Bar graphs (C-F) show the frequency of CD8+ T cell subsets quantified from multiplexed immunohistochemistry skin biopsy sections before and 9 weeks into the treatment. Total CD8+ cell count decreased in the skin tissue at week 9 into the treatment (C). However, increased proportions of CD8+CD137+ (D) and CD8+PD-1+ (E) activated T cells as well as CD8+CD103+ tissue resident effector/memory T cells (F) in the skin tissue at week 9, compared with pre-treatment, suggest that these cells contribute to the elimination of cutaneous metastases in situ.

    Techniques Used: Expressing, Derivative Assay, Sequencing, Recombinant, Immunohistochemistry, Cell Counting, In Situ

    Related Articles

    Synthesized:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).

    Derivative Assay:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).

    Expressing:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).

    Sequencing:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).

    Recombinant:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).

    Immunohistochemistry:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).

    Cell Counting:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).

    In Situ:

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab
    Article Snippet: After 24 h of culture, the cells were stained with the following antibodies: CD3, CD4, CD8, CD137 (BD Biosciences, San Diego, CA) and analyzed by flow cytometry (BD FACSCelesta, BD Biosciences, San Jose, CA).



    Similar Products

    pool 138 peptides derived cmv pp65 protein epitopes  (BEI Resources)
    90
    BEI Resources pool 138 peptides derived cmv pp65 protein epitopes
    p53MVA/pembrolizumab activate persistent p53-specific CD8+ T cell responses in the blood the timing of which correlates with lymphocytic infiltration of the resolved dermal metastases. The response of CD8+ (A) and CD4+ (B) T cells from PBMCs after 24-h stimulation culture with p53MVA, MVA, p5396, and pp65138, as determined by flow cytometric analysis. The upregulation of CD137 expression on the surface of CD3+CD8+ T cells reflects increased frequencies of p53-specific T cells in the circulation after vaccination, particularly between weeks 9 and 24. Culture conditions: NIL – medium alone; p53(96) – pool of peptides derived from wild type p53 sequence; <t>pp65(138)</t> – control peptides derived from pp65 <t>CMV;</t> MVA – wild type MVA vaccinia virus; p53MVA – recombinant MVA virus. Bar graphs (C-F) show the frequency of CD8+ T cell subsets quantified from multiplexed immunohistochemistry skin biopsy sections before and 9 weeks into the treatment. Total CD8+ cell count decreased in the skin tissue at week 9 into the treatment (C). However, increased proportions of CD8+CD137+ (D) and CD8+PD-1+ (E) activated T cells as well as CD8+CD103+ tissue resident effector/memory T cells (F) in the skin tissue at week 9, compared with pre-treatment, suggest that these cells contribute to the elimination of cutaneous metastases in situ.
    Pool 138 Peptides Derived Cmv Pp65 Protein Epitopes, supplied by BEI Resources, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pool+138+peptides+derived+cmv+pp65+protein+epitopes/pool+138+peptides+derived+cmv+pp65+protein+epitopes/pmc05706612-238-68-77
    Average 90 stars, based on 1 article reviews
    pool 138 peptides derived cmv pp65 protein epitopes - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    p53MVA/pembrolizumab activate persistent p53-specific CD8+ T cell responses in the blood the timing of which correlates with lymphocytic infiltration of the resolved dermal metastases. The response of CD8+ (A) and CD4+ (B) T cells from PBMCs after 24-h stimulation culture with p53MVA, MVA, p5396, and pp65138, as determined by flow cytometric analysis. The upregulation of CD137 expression on the surface of CD3+CD8+ T cells reflects increased frequencies of p53-specific T cells in the circulation after vaccination, particularly between weeks 9 and 24. Culture conditions: NIL – medium alone; p53(96) – pool of peptides derived from wild type p53 sequence; pp65(138) – control peptides derived from pp65 CMV; MVA – wild type MVA vaccinia virus; p53MVA – recombinant MVA virus. Bar graphs (C-F) show the frequency of CD8+ T cell subsets quantified from multiplexed immunohistochemistry skin biopsy sections before and 9 weeks into the treatment. Total CD8+ cell count decreased in the skin tissue at week 9 into the treatment (C). However, increased proportions of CD8+CD137+ (D) and CD8+PD-1+ (E) activated T cells as well as CD8+CD103+ tissue resident effector/memory T cells (F) in the skin tissue at week 9, compared with pre-treatment, suggest that these cells contribute to the elimination of cutaneous metastases in situ.

    Journal: Oncoimmunology

    Article Title: Complete regression of cutaneous metastases with systemic immune response in a patient with triple negative breast cancer receiving p53MVA vaccine with pembrolizumab

    doi: 10.1080/2162402X.2017.1363138

    Figure Lengend Snippet: p53MVA/pembrolizumab activate persistent p53-specific CD8+ T cell responses in the blood the timing of which correlates with lymphocytic infiltration of the resolved dermal metastases. The response of CD8+ (A) and CD4+ (B) T cells from PBMCs after 24-h stimulation culture with p53MVA, MVA, p5396, and pp65138, as determined by flow cytometric analysis. The upregulation of CD137 expression on the surface of CD3+CD8+ T cells reflects increased frequencies of p53-specific T cells in the circulation after vaccination, particularly between weeks 9 and 24. Culture conditions: NIL – medium alone; p53(96) – pool of peptides derived from wild type p53 sequence; pp65(138) – control peptides derived from pp65 CMV; MVA – wild type MVA vaccinia virus; p53MVA – recombinant MVA virus. Bar graphs (C-F) show the frequency of CD8+ T cell subsets quantified from multiplexed immunohistochemistry skin biopsy sections before and 9 weeks into the treatment. Total CD8+ cell count decreased in the skin tissue at week 9 into the treatment (C). However, increased proportions of CD8+CD137+ (D) and CD8+PD-1+ (E) activated T cells as well as CD8+CD103+ tissue resident effector/memory T cells (F) in the skin tissue at week 9, compared with pre-treatment, suggest that these cells contribute to the elimination of cutaneous metastases in situ.

    Article Snippet: In the initial analysis PBMC were thawed and plated at 2 × 10 5 cells/0.2 ml/well in media (RPMI, FBS 10%, glutamine 2 mM, sodium pyruvate 1 mM, non-essential amino acids) with one of the following stimuli: media alone, p53MVA, MVA, pool of 96 15-mer overlapping peptides spanning the entire length of p53 (p53 96 ; 5 μg/ml; synthesized in-house), and a pool of 138 peptides derived from CMV pp65 protein epitopes (pp65 138 ; 2 μg/ml; BEI Resources, NIH, Bethesda).

    Techniques: Expressing, Derivative Assay, Sequencing, Recombinant, Immunohistochemistry, Cell Counting, In Situ